Here's What's Causing Investors to Sell La Jolla Pharmaceutical Shares Today
After industry watchers at J.P. Morgan downgraded shares to an underweight rating, La Jolla Pharmaceutical Company (NASDAQ: LJPC) was nosediving 12.6% at 1 p.m. EST.
La Jolla Pharmaceutical reported positive phase 3 results earlier this year for LJPC-501, a drug that may help people suffering from a life-threatening drop in blood pressure. The company followed up that news with a filing for approval from the U.S. Food and Drug Administration; a decision is expected on Feb. 28, 2018.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
